DWA
PDSB icon

Dorsey Wright & Associates’s PDS Biotechnology PDSB Stock Holding History

Dorsey Wright & Associates’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,425
Closed -$66K – 322
2021
Q3 		$66K Buy
4,425
+348
+9% +$4.34K 0.01% 163
2021
Q2 		$51K Buy
+4,077
New +$31.8K 0.01% 190

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dorsey Wright & Associates's PDSB Position: Q4 2021 in Review

Dorsey Wright & Associates sold out of PDS Biotechnology (PDSB) in Q4 2021, closing a stake of 4,425 shares — an estimated $66K sold.

Dorsey Wright & Associates first reported a position in PDSB in Q2 2021 and held it in 2 quarters. The position peaked at $66K in Q3 2021. 65 funds tracked by Wall St. Rank hold PDSB as of Q4 2021.

  • Dorsey Wright & Associates reported no remaining PDS Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 4,425 PDS Biotechnology shares in Q4 2021, an estimated $66K.
  • Dorsey Wright & Associates first reported a position in PDS Biotechnology in Q2 2021 and held it in 2 quarters.
  • Dorsey Wright & Associates's PDS Biotechnology position peaked at $66K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2021.

Based on Dorsey Wright & Associates's 13F filing for Q4 2021, filed 27 Jan 2022.